ION Crossover Partners

ION Crossover Partners, based in Herzliya, is a crossover fund designed to write large checks into late-stage Israeli private technology companies preparing for public listings or major strategic exits. The fund’s posture is distinctive in the Israeli market because of both the size of its checks and its orientation toward the late-private and public-market interface, which most local venture firms do not cover. For AI healthcare founders running scaled software and health-IT businesses approaching the public markets, ION is one of the few credible options in the region.

The relevant thesis covers digital health and health-IT companies that have reached meaningful scale, often approaching or exceeding $100M in revenue or its enterprise value equivalent, with sustained growth, defensible margins, and operating discipline that supports public-market valuation. AI is treated as an enabling layer rather than a separate vertical, and the fund evaluates companies on the underlying business quality regardless of how AI is positioned in marketing. Pre-IPO companies, late-stage privates considering dual-track processes, and selected public companies in special situations are within scope.

Check sizes are in the $25M and above range, deployed at the growth and pre-IPO stage. ION participates as a lead or significant co-investor in late-private rounds and is comfortable with the unique dynamics of crossover investing, including holding through public-market transitions. Geography is principally Israel, with companies typically operating globally and pursuing US listings or strategic exits. Syndicate partners include US crossover investors, public-market specialists, and selected strategic investors.

The team includes partners with backgrounds in late-stage and public investing, the Israeli technology ecosystem, and the specific dynamics of crossover transactions. Board engagement is appropriate to the late stage, with help focused on capital markets readiness, governance, public-company operating discipline, and downstream financing. The fund operates with the rigor expected from a public-markets-adjacent investor.

Founders should approach ION when the company is genuinely at scale, when financial discipline and reporting are mature, and when an IPO or major strategic transaction is a realistic option within a defined window. Introductions through investment banks, late-stage growth investors, or board members with public-market experience are the most efficient path in. The right time to engage is twelve to twenty-four months before a planned listing or major transaction, allowing the fund to track progress and structure participation. Founders running earlier-stage companies should focus on stage-aligned specialists. For founders running mature, public-track AI healthcare and health-IT companies who need a serious crossover partner with Israeli market depth, ION offers capital and capital-markets capability that few other regional firms can provide.